ALB and type 2 diabetes mellitus: The biomarker panel (miR342, NFKB1, miR636, albumin-to-creatinine ratio, HDLc) bridges mechanistic depth (autophagy-inflammation axis) and clinical scalability, aligns with established pathways in T2DM pathogenesis while introducing novel insights into disease progression and complications outperforms isolated GWAS/proteomic markers in personalized risk stratification.